Curated News
By: NewsRamp Editorial Staff
October 08, 2026
Newron Reviews FDA Clinical Hold on Evenamide Phase 3 ENIGMA-TRS 2
TLDR
- Newron's evenamide shows lower mortality than placebo and could lead the treatment-resistant schizophrenia market.
- Newron received FDA feedback on a clinical hold and will respond after reviewing evenamide safety data.
- Newron advances evenamide for treatment-resistant schizophrenia to improve lives and life expectancy.
- Evenamide is a first-in-class glutamate modulator with over 10,000 ECGs collected in trials.
Impact - Why it Matters
This news matters because it directly affects Newron’s development of evenamide, a potential breakthrough for treatment-resistant schizophrenia, a condition that drastically reduces life expectancy and has limited effective treatments. The FDA’s clinical hold on U.S. study centers for ENIGMA-TRS 2 introduces a significant regulatory hurdle that could delay the program’s timeline and, if unresolved, jeopardize the availability of a much-needed therapy. The safety signal—four deaths among evenamide-treated patients versus one on placebo—raises legitimate concerns, but Newron’s extensive safety database and the lower mortality rate when adjusted for treatment duration suggest the picture may be more nuanced. For patients with treatment-resistant schizophrenia, who often endure debilitating side effects from existing antipsychotics and face a 20-year reduction in lifespan, evenamide represents a novel mechanism of hope. How the FDA and Newron resolve this hold will determine whether this promising therapy can advance, impacting investors, clinicians, and most importantly, patients awaiting better options.
Summary
Newron Pharmaceuticals S.p.A., a biopharmaceutical company specializing in central and peripheral nervous system therapies, has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on U.S. study centers for its Phase 3 ENIGMA-TRS 2 trial of evenamide. The FDA’s concern centers on the known risk that sodium channel blockers like evenamide may trigger arrhythmias leading to serious cardiovascular events or seizures. According to the FDA, four deaths occurred among patients treated with evenamide across all clinical studies, versus one death among placebo patients. Three of the evenamide deaths were considered unrelated by investigators, but one was classified as “possibly related” due to inconclusive autopsies. The FDA characterized these as a potential safety signal based on a possible fatal arrhythmic mechanism, despite evenamide’s known small QTc shortening and no established risk threshold for such shortening. Newron is thoroughly reviewing the feedback and the full body of safety data, which includes over 10,000 ECGs from approximately 700 evenamide-treated subjects and input from independent cardiac electrophysiologists. The company has not observed a pattern of cardiac abnormalities or arrhythmias to date.
Ravi Anand, MD, Chief Medical Officer of Newron, expressed confidence in the ENIGMA-TRS studies and the potential of evenamide for treatment-resistant schizophrenia, emphasizing that patient safety remains the utmost priority. He noted that the mortality rate adjusted for treatment duration was lower for evenamide (1.31 per 100 patient-years) than for placebo (1.81 per 100 patient-years). Professor Dr. Peter Falkai of LMU University of Munich highlighted the devastating impact of schizophrenia, which reduces life expectancy by about 10 years and by 20 years for treatment-resistant cases. Newron continues to advance the ENIGMA-TRS program: ENIGMA-TRS 1 enrollment is expected to complete by mid-October 2026, with topline 12-week data anticipated in Q1 2027, while ENIGMA-TRS 2 enrollment proceeds outside the U.S. with additional sites being added. The company will host an investor update call today at 3:30 pm CEST, with access details available here. Newron’s lead compound evenamide is a first-in-class glutamate modulator with the potential to be the first add-on therapy for treatment-resistant schizophrenia.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Newron Reviews FDA Clinical Hold on Evenamide Phase 3 ENIGMA-TRS 2
